Plasma Vanin-1 as a Novel Biomarker of Sepsis for Trauma Patients: A Prospective Multicenter Cohort Study.

INTRODUCTION: Vanin-1 plays a pivotal role in oxidative stress and the inflammatory response. However, its relationship with traumatic sepsis remains unknown. The aim of our study was to evaluate whether plasma vanin-1 could be used for the early prediction of traumatic sepsis.
METHODS: In this three-stage prospective cohort study, severe trauma patients admitted from January 2015 to October 2018 at two hospitals were enrolled. Plasma vanin-1 levels were measured by enzyme-linked immunosorbent assay (ELISA). The associations among variables and traumatic sepsis were identified by logistic regression models and the receiver operating characteristic (ROC) curve was analyzed to evaluate the diagnostic efficiency.
RESULTS: A total of 426 trauma patients (22 in the discovery cohort, 283 in the internal test cohort, and 121 in the external validation cohort) and 16 healthy volunteers were recruited. The plasma vanin-1 of trauma patients was significantly higher than that of healthy volunteers (P < 0.05). Patients with sepsis had higher plasma vanin-1 than patients without sepsis in the discovery trauma cohort (P < 0.05). In the internal test cohort, plasma vanin-1 at day 1 after trauma was significantly associated with the incidence of sepsis (OR = 3.92, 95% CI 2.68-5.72, P = 1.62 × 10-12). As a predictive biomarker, vanin-1 afforded a better area under the curve (AUC) (0.82, 95% CI 0.77-0.87) than C-reaction protein (CRP) (0.62, 95% CI 0.56-0.68, P < 0.0001), procalcitonin (PCT) (0.66, 95% CI 0.60-0.71, P < 0.0001), and Acute Physiology and Chronic Health Evaluation II (APACHE II) (0.71, 95% CI 0.65-0.76, P = 6.70 × 10-3). The relevance was further validated in the external validation cohort (OR = 4.26, 95% CI 2.22-8.17, P = 1.28 × 10-5), with an AUC of 0.83 (95% CI 0.75-0.89). Vanin-1 could also improve the diagnostic efficiency of APACHE II (AUC = 0.85).
CONCLUSIONS: Our study demonstrated that plasma vanin-1 increased among trauma patients and was independently associated with the risk of sepsis. Vanin-1 might be a potential biomarker for the early prediction of traumatic sepsis. TRIAL REGISTRATION: Clinicaltrials.gov Identifier, NCT01713205.

Key Summary Points

Digital Features

This article is published with digital features, including a summary slide, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.13691686.

Introduction

Sepsis is one of the most common complications and the leading cause of in-hospital death for severe trauma patients [1, 2]. Sepsis results in a longer length of hospital stay and higher health care costs, which greatly increases the burden on society [3, 4]. However, the diagnosis of post-traumatic sepsis is notoriously difficult in the sense that trauma patients are in a state of “sterile inflammation” [5]. The strong oxidative stress induced by severe injury may produce a genomic storm with alteration of up to 80% of the leukocyte transcriptome, thereby largely affecting the parameters used to diagnose sepsis [6]. Considering the consequences of sepsis after trauma, early recognition and individualized therapy of those patients at high risk of sepsis are essential prerequisites to reduce the morbidity of trauma patients [7, 8]. Therefore, an ideal biomarker is required to facilitate the early prediction of post-injury sepsis.

Vanin-1 (vascular non-inflammatory molecule 1, VNN1) is a pantetheinase that hydrolyzes pantetheine to pantothenic acid (vitamin B5) and cysteamine. Beyond its function in coenzyme A (CoA) metabolism, VNN1 has been found to participate in both oxidative stress and the inflammatory response [9, 10]. VNN1−/− mice showed increased tolerance to oxidative stress caused by gamma-radiation or paraquat intoxication [11]. In addition, they showed an attenuated inflammatory reaction after infection by schistosomiasis [12] or rickettsiosis [13]. In patients with multiple injuries, physical damage is the initiating factor in the production of oxygen free radicals and inflammatory reactions, and numerous studies have demonstrated associations between injury and elevated oxidative stress and inflammation [14]. Therefore, we hypothesized that vanin-1 might increase in response to physiological stress in trauma patients and might act as a potential predictive biomarker of traumatic sepsis.

In the present study, we detected the change of plasma vanin-1 levels in trauma patients. Then, we investigated the relationship between vanin-1 expression and incidence of sepsis. In addition, a prospective cohort study was conducted to evaluate the predictive power of plasma vanin-1 for traumatic sepsis. Finally, an independent cohort was conducted to validate these findings. Our aim is to determine whether plasma vanin-1 could act as a potential biomarker for the early diagnosis of sepsis in trauma patients.

Methods

Study Design and Setting

The present study was a two-center, prospective cohort investigation. Severe trauma patients with an Injury Severity Score (ISS) greater than 16 points and admitted to the hospital within 24 h post injury were enrolled in parallel from the ICU at the Department of Trauma Surgery from Daping Hospital and the Central Hospital of Chongqing University from January 2015 to October 2018. Patients who met one of the following criteria were excluded: (1) age less than 15 years old or more than 65 years old; (2) pregnancy; (3) malignant tumor; (4) serious chronic history of cardiovascular, respiratory, renal, hepatic, hematologic, or immunological diseases. Sixteen healthy volunteers were asymptomatic nonsmokers under 65 years of age, who had no known chronic medical conditions.

This study included a discovery cohort and two test cohorts. Patients were followed up during the hospital stay and divided into sepsis and non-sepsis groups during data analysis according to the occurrence of sepsis, which was defined as a suspected infection with an acute change in SOFA scores of at least 2 (Sepsis-3) [15]. For those patients with sepsis enrolled before 2016 and first diagnosed on the basis of Sepsis-2, we invited clinical doctors to reanalyze whether the patients met the definition of Sepsis-3. The definition of infection was a clinically obvious source or positive bacterial culture. The research was approved by the Institutional Ethics Review Board of the Army Medical University. The study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. Informed consent of all patients was obtained from the patients or their relatives. The National Clinical Trial number is NCT01713205, registered on 22 October 2012.

Data Collection

Demographic characteristics and clinical data, including general condition, vital signs, and consciousness state, were retrieved from the electronic medical records. Acute Physiology and Chronic Health Evaluation (APACHE) II scores and Sequential Organ Failure Assessment (SOFA) scores were calculated to evaluate the disease severity and organ failures.

Detection of Vanin-1 in Plasma

Blood specimens were collected and processed as previously reported [2, 16]. Briefly, whole blood was collected using an EDTA-coated tube immediately after admission and kept at 4 °C. Sample was centrifuged within 1 h at 3000 rpm for 5 min at 4 °C. The plasma was separated and stored at − 80 °C for further analyses. To test the dynamic change in plasma vanin-1, blood samples at days 1, 3, 5, 7, and 14 after injury were collected in the discovery cohort. The basic levels of plasma vanin-1 were measured among 16 healthy volunteers. A commercially available enzyme-linked immunosorbent assay (ELISA) (Cloud-Clone Corp, USA) was conducted to detect vanin-1 in plasma. Vanin-1 levels were determined in duplicate following the manufacturer’s instructions.

Statistical Analysis

Categorical variables were summarized as number and proportion, and the differences were compared with the χ2 test. Continuous variables were expressed as the median and standard deviation (SD), and comparisons of the mean were performed using Student’s t test or Mann–Whitney U test. The associations among variables and traumatic sepsis were identified by logistic regression models. Additionally, we adjusted for age, sex, and ISS to correct the associations. The evaluation of the predictive accuracy was performed using the area under the curve (AUC) of the receiver operating characteristic (ROC) curve. The correlations between vanin-1 and other variables were assessed using Spearman rank correlation coefficient. Differences with P < 0.05 were statistically significant. All statistical analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, USA) and MedCalc version 13 (MedCalc Software, Ostend, Belgium).

Results

Clinical Data and General Information

In total, 426 patients suffering from severe injury were enrolled in our study, including 305 patients (11 patients with sepsis and 11 patients without sepsis were randomly selected as the discovery cohort, and the remaining 283 patients as the internal test cohort) from Daping Hospital, and 121 patients from Chongqing Emergency Medical Center as the external validation cohort. The age, gender, injuries, and infections among the three groups were comparable (Table 1). Most patients developed sepsis 3–5 days after injury. Gram-negative bacteria were the main pathogenic microorganisms. Just a few patients with sepsis tested positive for Gram-positive bacteria or had mixed infection. Pneumonia and primary bloodstream infections were the major infection sites. The mortality of both cohorts was relatively low, 3.18% and 2.48%, respectively.

Table 1

Clinical characteristics of trauma patients

Variables	Discovery cohort (n = 22)	Internal test cohort (n = 283)	External validation cohort (n = 121)	P value*
Gender (female/male)	4/18	59/224	28/93	0.90
Age (years)	44.75 ± 15.02	43.39 ± 12.01	44.48 ± 12.65	0.68
ISS	26.85 ± 9.19	24.45 ± 8.44	22.97 ± 8.56	0.10
AISHead/neck	2.55 ± 1.76	1.80 ± 1.67	1.80 ± 1.65	0.10
AISFace	0.40 ± 0.60	0.43 ± 0.79	0.28 ± 0.59	0.12
AISThorax	3.05 ± 1.23	2.71 ± 1.26	3.01 ± 1.06	0.43
AISAbdomen	1.65 ± 1.66	1.26 ± 1.52	1.30 ± 1.32	0.47
AISUpper/lower extremity	1.70 ± 1.13	2.17 ± 1.49	1.95 ± 1.63	0.07
GCS initial	13.85 ± 6.16	14.00 ± 3.00	13.78 ± 2.68	0.32
APACHE II scores initial	7.85 ± 3.76	7.67 ± 6.31	7.40 ± 4.57	0.92
SOFA scores initial	1.85 ± 1.18	2.95 ± 2.22	2.28 ± 1.41	0.10
Sepsis, n (%)	–	91 (32.16%)	41 (33.88%)	0.73
Pathogens, n (%)				0.46
Gram-negative	–	62 (68.13%)	21 (51.22%)
Gram-positive	–	11 (12.09%)	8 (19.51%)
Mixed Gram-negative and Gram-positive	–	7 (7.69%)	5 (12.20%)
Others	–	4 (4.40%)	2 (4.87%)
Negative blood cultures	–	7 (7.69%)	5 (12.20%)
Source of infection, n (%)				0.41
Blood	–	25 (27.47%)	10 (24.39%)
Sputum	–	27 (29.68%)	13 (31.71%)
Urine	–	15 (16.48%)	8 (19.51%)
Secretions	–	18 (19.78%)	4 (9.76%)
Others	–	6 (6.59%)	6 (14.63%)
Time trauma–sepsis onset, days	5.85 ± 2.91	5.76 ± 4.82	5.03 ± 2.52	0.72
ICU days	6.16 ± 9.22	4.47 ± 7.92	5.76 ± 13.01	0.99
Deaths	0 (0.00%)	9 (3.18%)	3 (2.48%)	0.66

ISS Injury Severity Score, AIS Abbreviated Injury Scale, GCS Glasgow Coma Scale, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment

*Categorical variables were compared using the χ2 test and continuous variables were compared using analysis of variance (ANOVA) test

Dynamic Change of Plasma Vanin-1 After Injury

The mean plasma vanin-1 levels were 0.66 (0.61–0.70) ng/ml for healthy population. Trauma patients had the highest plasma vanin-1 on the first day of admission (1.73 ± 1.07 ng/ml, P = 1.21 × 10−4, discovery cohort) (Fig. 1a). Then, the level of vanin-1 gradually declined from day 3 to day 14 after injury but was still significantly higher than that of healthy controls (P < 0.01 for all days). We further compared plasma levels of vanin-1 between the sepsis and the non-sepsis group. Significantly elevated plasma levels of vanin-1 were found in patients with sepsis, especially on early days after admission (P = 0.03 for day 1 and P = 0.04 for day 3), indicating the potentially predictive value of vanin-1 levels for sepsis in trauma patients (Fig. 1b). No significant difference was demonstrated between two groups at days 5, 7, and 14.

Fig. 1

Kinetics of plasma vanin-1 levels in trauma patients on admission and at days 3, 5, 7, and 14 during hospitalization from the discovery cohort. a Plasma vanin-1 of trauma patients is significantly higher than that of healthy volunteers (n = 22 trauma patients vs. 16 healthy controls). b Trauma patients with sepsis have higher plasma vanin-1 than patients without sepsis at the early stage after injury (n = 11 patients with sepsis vs. 11 patients without sepsis, P = 0.03 for day 1 and P = 0.04 for day 3). Data are expressed as the mean and 95% CI. Statistical analysis comprised Student’s t test

Predictive Value of Plasma Vanin-1 in Trauma Patients

To investigate whether plasma vanin-1 could be used as a predictive biomarker of traumatic sepsis, we evaluated the predictive power of plasma vanin-1 at day 1 in 283 trauma patients (internal test cohort). Our results showed a strong association between higher plasma vanin-1 levels taken 24 h post injury and the incidence of secondary sepsis within the subsequent 14 days (P = 6.02 × 10−13) (Fig. 2a). No significant correlation between ISS and plasma vanin-1 was observed (r2 = 0.01, P = 0.06). In addition, our results demonstrated that the level of plasma vanin-1 at day 1 was significantly associated with the incidence of sepsis in patients after trauma (OR = 3.89, 95% CI 2.68–5.63, P = 6.99 × 10−13) (Table S1 in the supplementary material). Logistic regression analyses also demonstrated that plasma vanin-1 was significantly related to a higher occurrence of sepsis adjusted for age, sex, smoking, drinking, and ISS (OR = 3.92, 95% CI 2.68–5.72, P = 1.67 × 10−12, Table 2). On the basis of the ROC analysis of plasma vanin-1 at day 1, an AUC of 0.82 (95% CI 0.77–0.87) was obtained for the morbidity of sepsis after trauma (Fig. 3a). The optimal cutoff value was 1.41 ng/ml in the internal test cohort with the sensitivity and specificity of 70.00% and 84.90%, respectively (Table S2 in the supplementary material). Although CRP, PCT, and APACHE II at day 1 after trauma were also associated with the risk of traumatic sepsis in our internal test cohort (Tables S1 and S2 in the supplementary material, and Table 2), our results revealed that vanin-1 had a better AUC than other biomarkers (CRP, P < 0.0001; PCT, P < 0.0001; APACHE II, P = 6.70 × 10−3) (Fig. 3a).

Fig. 2

Plasma vanin-1 in trauma patients with and without sepsis for the a internal test and b external validation cohorts. Patients who developed sepsis had significantly higher levels of plasma vanin-1 when compared with patients who did not develop sepsis at day 1 after trauma. All samples were collected on day 1 after injury. Black bars show the mean and 95% CI. Statistical analysis comprised Student’s t test

Table 2

Associations between each biomarker and traumatic sepsis in adjusted logistic regression models

Variables	Internal test cohort		External validation cohort
	OR (95% CI)	P*	OR (95% CI)	P*
APACHE II	1.17 (1.10–1.23)	5.35 × 10−8	1.21 (1.08–1.37)	1.00 × 10−3
PCT	1.06 (1.02–1.10)	2.00 × 10−3	0.99 (0.90–1.08)	0.86
CRP	1.01 (1.00–1.01)	3.00 × 10−3	1.01 (1.00–1.02)	0.05
Vanin-1	3.92 (2.68–5.72)	1.62 × 10−12	4.26 (2.22–8.17)	1.28 × 10−5

APACHE II Acute Physiology and Chronic Health Evaluation II, PCT procalcitonin, CRP C-reactive protein

*Adjusted for age, sex, smoking, drinking, and ISS

Fig. 3

Receiver operating curve (ROC) analysis of VNN1, CRP, PCT, and APACHE II for sepsis after trauma. Plasma vanin-1 afforded the best predictive value compared to other biomarkers and scores in the internal test cohort (a, n = 283) and external validation cohort (b, n = 121)

Validation of Vanin-1 for Predict Sepsis in Trauma Patients

We further validated the predictive ability of plasma vanin-1 at day 1 after injury in the external validation cohort. In this cohort, plasma vanin-1 was also not associated with ISS (r2 = 0.03, P = 0.07). Patients with sepsis had significant higher plasma vanin-1 than patients without sepsis at day 1 after injury (P = 8.39 × 10−6) (Fig. 2b). Plasma vanin-1 at day 1 after injury was also associated with the risk of sepsis, adjusted for age, sex, smoking, drinking, and ISS (OR = 4.26, 95% CI 2.22–8.17, P = 1.28 × 10−5, Table 2). Plasma vanin-1 afforded an AUC of 0.83 (95% CI 0.75–0.89) for the incidence of sepsis after trauma (Fig. 3b). The optimal cutoff value was 1.35 ng/ml in the external validation cohort, with a sensitivity and specificity of 70.73% and 90.00%, respectively (Table S1 in the electronic supplementary material for details). We also analyzed the associations between CRP, PCT, APACHE II, and traumatic sepsis. Except for the PCT, the remaining CRP and APACHE II were related to the risk of sepsis after trauma (Table 2 and Table S2 in the electronic supplementary material). When compared with CRP (AUC = 0.59, 95% CI 0.500–0.68, P = 1.20 × 10−3), PCT (AUC = 0.63, 95% CI 0.54–0.71, P = 1.30 × 10−3), and APACHE II (AUC = 0.72, 95% CI 0.63–0.80, P = 0.09), vanin-1 also afforded a better predictive ability (Fig. 3b and Table 3). Furthermore, combining plasma vanin-1 with APACHE II increased the diagnostic efficiency (AUC = 0.85, Table 3).

Table 3

Predictive probability of single predictor in trauma cohort

Variables	Internal test cohort						External validation cohort
	AUC	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	Cutoff	AUC	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	Cutoff (%)
CRP	0.62 (0.56–0.68)	37.36	84.37	53.1	74.0	79.8	0.59 (0.50–0.68)	78.05	43.75%	41.6	79.5	3
PCT	0.66 (0.60–0.71)	67.03	59.90	44.2	79.3	0.67	0.63 (0.54–0.71)	80.49	40.00%	40.7	80.0	0.219
APACHE II	0.71 (0.65–0.76)	62.64	69.29	49.1	79.6	6	0.72 (0.63–0.80)	78.05	56.25%	47.8	83.3	6
Vanin-1	0.82 (0.77–0.87)	70.33	84.90	68.8	85.8	1.41	0.83 (0.75–0.89)	70.73	90.00%	78.4	85.7	1.35
APACHE II + vanin-1	0.85 (0.80–0.89)	70.45	86.98	–	–	–	0.87 (0.80–0.93)	80.49	87.50%	–	–	–

CRP C-reactive protein, PCT procalcitonin, APACHE II Acute Physiology and Chronic Health Evaluation II, AUC area under curve, PPV positive predictive value, NPV negative predictive value

Discussion

Increasing evidence has highlighted the importance of vanin-1 in various cancer and inflammatory disorders, including septic shock [17]. However, whether vanin-1 could be used as a biomarker for early warning of traumatic sepsis was still unknown. In this study, elevated admission plasma vanin-1 levels were observed in severe trauma patients. We have demonstrated that increased admission vanin-1 was significantly associated with the incidence of sepsis in severe trauma patients. Furthermore, after adjustment for age, sex, smoking, drinking, and ISS, vanin-1 was strongly associated with sepsis. When plasma vanin-1 was used as a biomarker for the early prediction of traumatic sepsis, better predictive abilities were obtained than PCT, CRP, and APACHE II in both of our internal test and external validation cohorts.

In previous studies, VNN1 mRNA had been used to predict the risk or prognosis of patients with colorectal cancer [18, 19] and patients with acute myeloid leukemia [20]. Elevated circulation or urinary vanin-1 has been reported in acute/chronic kidney injury [21, 22], drug-induced renal injury [23], and patients with asthma [24]. We demonstrated in the current study that plasma vanin-1 increased rapidly after injury. Specially, patients who developed sepsis later had higher plasma vanin-1 on admission. It was consistent with the findings from our group through reanalyzing genome-wide expression of leukocytes from trauma patients in a public trauma website (The Human Genomic Response to Severe Traumatic Injury, http://web.mgh.harvard.edu/TRT/). In this public database, VNN1 mRNA was upregulated and differentially expressed between the complicated recovery group and the uncomplicated recovery group within 12 h and at 1, 4, 7, 14, 21, and 28 days after injury. We further analyzed the public transcriptome data of patients with sepsis from the GEO dataset (https://www.ncbi.nlm.nih.gov/gds/). Upregulation of VNN1 mRNA in patients with sepsis was obviously detected in the GSE28750 [25], GSE64457 [26], and GSE46995 [27]. It has been controversial whether PCT and CRP could be used to predict the incidence of sepsis in trauma patients [28]. In this study, we showed that both PCT and CRP were not suitable for diagnosing sepsis in severe trauma patients, and have low sensitivity or specificity. In our two larger trauma cohorts, plasma vanin-1 at day 1 after trauma was independently associated with the incidence of traumatic sepsis even after adjustment for age, sex, smoking, drinking, and ISS in the multiple logistic regression analysis. Since the internal test cohort and external validation cohort were enrolled from two different hospitals, we considered it was more reasonable to reanalyze the cutoff. Fortunately, the cutoff value in the internal test cohort was consistent with that of the external validation cohort (1.41 ng/ml vs. 1.35 ng/ml). Our results showed that plasma vanin-1 level on admission could be used to predict the risk of sepsis after trauma with an AUC over 0.80. Compared with CRP, PCT, and APACHE II, plasma vanin-1 outperformed the predicted ability in our study cohorts. When vanin-1 was combined with the APACHE II score, the AUC could be increased to 0.85. All of these findings supported increased vanin-1 in trauma patients, and plasma vanin-1 might be used as a potential biomarker of post-injury sepsis at an early stage. The potential relevance of plasma vanin-1 would help clinicians categorize high-risk patients with sepsis at the early stage of trauma and enable rapid treatment, improve outcomes, and reduce unnecessary antibiotic therapy.

To our knowledge, little has been known about the mechanisms of how vanin-1 influences the process of sepsis. VNN1 might play a protective role against oxidative stress and the inflammatory response caused by infection [29, 30]. Yamashita et al. reported vanin-1 elevation in patients with influenza A (H1N1) pneumonia [31]. Furthermore, VNN1 mRNA increased significantly in the human alveolar epithelial carcinoma cell line A549 in response to tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), IL-1β, lipopolysaccharides (LPS), and H2O2. These studies indicated that the strong oxidative stress caused by injury also induced the upregulation of VNN1 mRNA. In addition, injury and subsequent pro-inflammatory cytokines, such as TNFα and IL-1β, might upregulate VNN1 mRNA levels [31, 32]. Additionally, previous studies demonstrated that glutathione, the most potent cellular antioxidant, was elevated in VNN1−/− mice, resulting in a lack of cysteamine in tissues. Therefore, VNN1−/− mice exhibited resistance to oxidative damage and reduced inflammatory responses [11]. Moreover, there was a negative correlation between the expression levels of VNN1 and peroxisome proliferator-activated receptor-γ (PPARγ) [33]. PPARγ in monocytes plays an anti-inflammatory role by inhibiting other transcription factors, such as nuclear factor-κB and activator protein 1 [34, 35]. VNN1 promotes inflammation partly by inhibiting both PPARγ expression and signal transduction [32, 33]. Ling et al. suggested that VNN1 was negatively regulated by miR-203 and affected sepsis through the AKT signaling pathway. Therefore, we speculated that VNN1 played an important role in sepsis development by regulating the glutathione, cysteamine, PPARγ, and AKT signaling pathways. Further functional experiments might help us to clarify the role of VNN1 in sepsis development.

Some potential limitations of the present study should be considered. First, the sample size of patients in each cohort was relatively small, notably in the discovery cohort. Additional large studies with multiple ethnicities are needed to validate these findings. Second, we revealed that plasma vanin-1 levels were associated with traumatic sepsis. However, how vanin-1 affected the development of sepsis was unclear. More studies with cellular and molecular experiments were required to investigate the relevant mechanisms. Finally, although the correlations between plasma vanin-1 and traumatic sepsis were validated, whether the findings could be interpreted in other ethnic groups needs further evaluation.

Conclusion

Our study demonstrated that plasma vanin-1 on admission is independently associated with the risk of traumatic sepsis and has a good capacity to predict sepsis at the early stage of trauma. To confirm these findings, further studies with multiple populations and functional evaluations are warranted.

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 23 KB)

Sepsis has become the main cause of in-hospital death in severe trauma patients. New predictive clinical biomarkers with high specificity are urgently needed.

Vanin-1 was reported to play a pivotal role in oxidative stress and the inflammatory response. We hypothesized that vanin-1 might act as a potential predictive biomarker of traumatic sepsis.

Plasma vanin-1 increased among trauma patients and was independently associated with the risk of sepsis, especially in the first 3 days after injury.

There is a significant relationship between plasma vanin-1 and sepsis in both the internal test cohort and the external validation cohort. These results contribute to the body of evidence supporting the use of plasma vanin-1 in the early prediction of traumatic sepsis.

Further studies with multiple populations and functional experiments are needed.